文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

巨噬细胞凋亡抑制因子/CD5L作为预测脓毒症危重患者死亡率的生物标志物评估

Assessment of Apoptosis Inhibitor of Macrophage/CD5L as a Biomarker to Predict Mortality in the Critically Ill With Sepsis.
PubMed 文献 · Chest · 2019-05-30
一句话结论脓毒症患者入住ICU时血清AIM/CD5L水平升高与28天死亡率相关,在成人中预测死亡率AUC为0.86,高于SOFA、降钙素原、乳酸等指标。

该研究纳入150例成人脓毒症患者作为推导队列,检测入住ICU当天血清AIM水平,并与生存状态和器官功能障碍进行比较;另纳入来自另一医疗中心的60例成人脓毒症患者作为验证队列,并进一步在51例儿童脓毒症患者中探讨AIM作为结局预测因子的作用。结果显示,脓毒症患者入院时血清AIM水平较ICU对照和健康对照显著升高,较高的AIM水平与较高的SOFA评分显著相关;AIM预测28天死亡率的AUC为0.86,高于SOFA(0.77)、降钙素原(0.73)、乳酸(0.67)、IL-27(0.65)和C反应蛋白(0.55)。入院AIM水平>543.66 ng/mL的脓毒症患者28天死亡率显著高于AIM≤543.66 ng/mL者,该关联在成人验证队列中得到证实;儿童脓毒症队列中AIM预测28天死亡率的AUC为0.82。作者认为入院时循环AIM水平可作为预测死亡率的新型预后生物标志物。

要点

  • 成人脓毒症患者入住ICU当天血清AIM预测28天死亡率AUC为0.86,高于SOFA(0.77)、降钙素原(0.73)、乳酸(0.67)、IL-27(0.65)和C反应蛋白(0.55)。
  • 入院血清AIM>543.66 ng/mL的脓毒症患者28天死亡率显著高于AIM≤543.66 ng/mL者,该关联在另一医疗中心60例成人脓毒症验证队列中得到证实。
  • 脓毒症患者入院时血清AIM水平较ICU对照和健康对照显著升高,且较高的入院AIM水平与较高的SOFA评分显著相关。
  • 在51例儿童脓毒症患者队列中,AIM预测28天死亡率的AUC为0.82。

适用人群与场景

  • 成人脓毒症患者(推导队列150例,验证队列为来自另一医疗中心的60例成人脓毒症患者)。
  • 儿童脓毒症患者51例(用于进一步探讨AIM作为结局预测因子的作用)。

诊断标准与关键阈值

  • 入院血清AIM水平>543.66 ng/mL的脓毒症患者28天死亡率显著高于AIM≤543.66 ng/mL者。

研究设计与关键结果

  • 研究类型为生物标志物预后研究,成人推导队列150例,验证队列为来自另一医疗中心的60例成人脓毒症患者,另在51例儿童脓毒症患者中探讨AIM的结局预测作用。
  • 脓毒症患者入院时血清AIM水平较ICU对照和健康对照显著升高。
  • 较高的入院血清AIM水平与较高的SOFA评分显著相关。
  • 入住ICU当天AIM预测28天死亡率的AUC为0.86,高于SOFA(0.77)、降钙素原(0.73)、乳酸(0.67)、IL-27(0.65)和C反应蛋白(0.55)。
  • 入院AIM>543.66 ng/mL的脓毒症患者28天死亡率显著高于AIM≤543.66 ng/mL者,该关联在成人验证队列中得到证实。
  • 儿童脓毒症队列中AIM预测28天死亡率的AUC为0.82。

证据类型、等级与局限

  • 证据类型:生物标志物预后研究(推导队列+验证队列+儿童队列)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为入院时循环AIM水平可作为预测脓毒症患者死亡率的新型预后生物标志物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To determine the utility of apoptosis inhibitor of macrophage (AIM)/CD5L as a potentially novel biomarker of morbidity and mortality in patients with sepsis who are critically ill.

METHODS: There were 150 adult patients with sepsis studied. Serum AIM levels on day of ICU admission were determined and compared with survival status and organ dysfunction. For validation, 60 adult patients with sepsis from another medical center were studied. Furthermore, the role of AIM as an outcome predictor in 51 pediatric patients with sepsis was investigated.

RESULTS: In the derivation cohort of adult patients, patients with sepsis had markedly increased admission levels of serum AIM compared with ICU control subjects and healthy control subjects. Higher serum AIM levels at admission were significantly associated with higher Sequential (sepsis-related) Organ Failure Assessment (SOFA) scores. On day of ICU admission, the area under the receiver operating characteristic curve (AUC) for AIM level association with 28-day mortality was 0.86, higher than the AUC for SOFA (0.77), procalcitonin (0.73), lactate (0.67), IL-27 (0.65), and C-reactive protein (0.55). Patients with sepsis with higher admission levels of AIM (> 543.66 ng/mL) had significantly increased 28-day mortality compared with those with lower AIM levels (≤ 543.66 ng/mL). The association between admission levels of AIM and 28-day mortality was confirmed in the validation cohort of adult patients. In another cohort of pediatric patients with sepsis, the AUC for AIM level association with 28-day mortality was 0.82.

CONCLUSIONS: Circulating AIM levels at admission were markedly increased in patients with sepsis, which can serve as a novel prognostic biomarker for predicting mortality.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Gao X, Liu Y, Xu F, et al. Assessment of Apoptosis Inhibitor of Macrophage/CD5L as a Biomarker to Predict Mortality in the Critically Ill With Sepsis. Chest. 2019. PMID: 31154043. doi:10.1016/j.chest.2019.04.134

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。